参考文献/References:
[1] Koenig W,Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease:the epidemiological evidence[J]. Cardiovasc Drugs Ther,2009,23(1):85-92.
[2] Persson M,Nilsson JA,Nelson JJ,et al. The epidemiology of Lp-PLA(2):distribution and correlation with cardiovascular risk factors in a population-based cohort[J]. Atherosclerosis,2007,190(2):388-396.
[3] Unno N,Sakaguchi T,Nakamura T,et al. A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease[J]. J Surg Res,2006,134(1):36-43.
[4] Yamada Y,Yoshida H,Ichihara S,et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype,age,and atherosclerosis in a Japanese population[J]. Atherosclerosis,2000,150(1):209-216.
[5] Yamada Y,Ichihara S,Fujimura T,et al. Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men[J]. Metabolism,1998,47(2):177-181.
[6] Liu PY,Li YH,Wu HL,et al. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction[J]. J Thromb Haemost,2006,4(5):1023-1028.
[7] Sutton BS,Crosslin DR,Shah SH,et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase(PLA2G7) gene and cardiovascular disease in case-control and family datasets[J]. Hum Mol Genet,2008,17(9):1318-1328.
[8] Hou L,Chen S,Yu H,et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population:the Beijing atherosclerosis study[J]. Hum Genet,2009,125(1):11-20.
[9] Samanta U,Bahnson BJ. Crystal structure of human plasma platelet-activating factor acetylhydrolase:structural implication to lipoprotein binding and catalysis[J]. J Biol Chem,2008,283(46):31617-31624.
[10] Stafforini DM,Satoh K,Atkinson DL,et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase[J]. J Clin Invest,1996,97(12):2784-2791.
[11] Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH,lipoprotein associated phospholipase A2)[J]. Cardiovasc Drugs Ther,2009,23(1):73-83.
[12] Kruse S,Mao XQ,Heinzmann A,et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma[J]. Am J Hum Genet,2000,66(5):1522-1530.
[13] Casas JP,Ninio E,Panayiotou A,et al. PLA2G7 genotype,lipoprotein-associated phospholipase A2 activity,and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry[J]. Circulation,2010,121(21):2284-2293.
[14] Grallert H,Dupuis J,Bis JC,et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease:meta-analysis of genome-wide association studies from five community-based studies[J]. Eur Heart J,2012,33(2):238-251.
[15] Gregson JM,Freitag DF,Surendran P,et al. Genetic invalidation of Lp-PLA2 as a therapeutic target :Large-scale study of five functional Lp-PLA2-lowering alleles[J]. Eur J Prev Cardiol,2017,24(5):492-504.
[16] Qi Y,Zhao D,Jia Z,et al. A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass[J]. Sci Rep,2016,6:37465.
[17] Hoffmann MM,Winkler K,Renner W,et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)[J]. J Thromb Haemost,2009,7(1):41-48.
[18] Ferguson JF,Hinkle CC,Mehta NN,et al. Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis[J]. J Am Coll Cardiol,2012,59(8):764-772.
[19] Maiolino G,Lenzini L,Pedon L,et al. Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease[J]. J Cardiovasc Med (Hagerstown),2015,16(1):29-36.
[20] Yeo A,Li L,Warren L,et al. Pharmacogenetic meta-analysis of baseline risk factors,pharmacodynamic,efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib[J]. PLoS One,2017,12(7):e0182115.
[21] Ninio E,Tregouet D,Carrier JL,et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease[J]. Hum Mol Genet,2004,13(13):1341-1351.
[22] Miwa M,Miyake T,Yamanaka T,et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children[J]. J Clin Invest,1988,82(6):1983-1991.
[23] Karasawa K. Naturally occurring missense mutation in plasma PAF-AH among the Japanese population[J]. Enzymes,2015,38:117-143.
[24] Santoso A,Maulana R,Alzahra F,et al. Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis:a meta-analysis[J]. Am J Cardiovasc Dis,2017,7(6):122-133.
[25] Jang Y,Kim OY,Koh SJ,et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J]. J Clin Endocrinol Metab,2006,91(9):3521-3527.
[26] Jang Y,Waterworth D,Lee JE,et al. Carriage of the V279F null allele within the gene encoding Lp-PLA2 is protective from coronary artery disease in South Korean males[J]. PLoS One,2011,6(4):e18208.
[27] Liu X,Zhu RX,Tian YL,et al. Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population[J]. Clin Biochem,2014,47(6):404-408.
[28] Zheng GH,Xiong SQ,Chen HY,et al. Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population[J]. Mol Biol Rep,2014,41(11):7141-7151.
[29] Hong M,Zhang M,Lu X. Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population[J]. Mamm Genome,2015,26(3-4):191-199.
[30] Ma Y. Associations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke[J]. Biomed Rep,2016,4(2):246-250.
[31] Millwood IY,Bennett DA,Walters RG,et al. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults[J]. Int J Epidemiol,2016,45(5):1588-1599.
[32] Miwa Y,Kamide K,Takiuchi S,et al. Association of PLA2G7 polymorphisms with carotid atherosclerosis in hypertensive Japanese[J]. Hypertens Res,2009,32(12):1112-1118.
[33] Wu C,Zhou T,Zhou Y,et al. Association of serum lipoprotein-associated phospholipase A2 and A379V gene polymorphisms with carotid plaques[J]. Genet Test Mol Biomarkers,2020,24(3):131-137.
[34] Cai A,Zheng D,Qiu R,et al. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)):a novel and promising biomarker for cardiovascular risks assessment[J]. Dis Markers,2013,34(5):323-331.
[35] Bonnefont-Rousselot D. [Lp-PLA2,a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques][J]. Ann Pharm Fr,2016,74(3):190-197.
[36] Guerra R,Zhao B,Mooser V,et al. Determinants of plasma platelet-activating factor acetylhydrolase:heritability and relationship to plasma lipoproteins[J]. J Lipid Res,1997,38(11):2281-2288.
[37] Karasawa K,Harada A,Satoh N,et al. Plasma platelet activating factor-acetylhydrolase (PAF-AH)[J]. Prog Lipid Res,2003,42(2):93-114.
[38] Stafforini DM. Functional consequences of mutations and polymorphisms in the coding region of the PAF acetylhydrolase (PAF-AH) gene[J]. Pharmaceuticals (Basel),2009,2(3):94-117.
[39] Braun LT,Davidson MH. Lp-PLA2:a new target for statin therapy[J]. Curr Atheroscler Rep,2010,12(1):29-33.
[40] Tselepis AF,Rizzo M,Goudevenos IA. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)[J]. Curr Pharm Des,2011,17(33):3656-3661.
[41] Yeo A,Li L,Warren L,et al. Pharmacogenetic meta-analysis of baseline risk actors,harmacodynamic,efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib[J]. PLoS One,2017,12:e0182115.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(4):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[3]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(4):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[4]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[5]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[6]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[7]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[8]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[9]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[10]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]